Tectonic Therapeutic (TECX) Competitors $54.14 -0.70 (-1.28%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$56.22 +2.08 (+3.83%) As of 01/31/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TECX vs. HCM, MIRM, CGON, JANX, PTGX, VERA, HRMY, IBRX, CNTA, and BEAMShould you be buying Tectonic Therapeutic stock or one of its competitors? The main competitors of Tectonic Therapeutic include HUTCHMED (HCM), Mirum Pharmaceuticals (MIRM), CG Oncology (CGON), Janux Therapeutics (JANX), Protagonist Therapeutics (PTGX), Vera Therapeutics (VERA), Harmony Biosciences (HRMY), ImmunityBio (IBRX), Centessa Pharmaceuticals (CNTA), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry. Tectonic Therapeutic vs. HUTCHMED Mirum Pharmaceuticals CG Oncology Janux Therapeutics Protagonist Therapeutics Vera Therapeutics Harmony Biosciences ImmunityBio Centessa Pharmaceuticals Beam Therapeutics HUTCHMED (NASDAQ:HCM) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk. Does the MarketBeat Community believe in HCM or TECX? HUTCHMED received 307 more outperform votes than Tectonic Therapeutic when rated by MarketBeat users. However, 100.00% of users gave Tectonic Therapeutic an outperform vote while only 66.32% of users gave HUTCHMED an outperform vote. CompanyUnderperformOutperformHUTCHMEDOutperform Votes31566.32% Underperform Votes16033.68% Tectonic TherapeuticOutperform Votes8100.00% Underperform VotesNo Votes Do analysts rate HCM or TECX? HUTCHMED currently has a consensus target price of $19.00, suggesting a potential upside of 40.53%. Tectonic Therapeutic has a consensus target price of $80.50, suggesting a potential upside of 48.69%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is HCM or TECX more profitable? HUTCHMED's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A Tectonic Therapeutic N/A -35.53%-31.97% Does the media favor HCM or TECX? In the previous week, Tectonic Therapeutic had 20 more articles in the media than HUTCHMED. MarketBeat recorded 24 mentions for Tectonic Therapeutic and 4 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.36 beat Tectonic Therapeutic's score of 0.44 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 5 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, HCM or TECX? HUTCHMED has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 2.63, indicating that its stock price is 163% more volatile than the S&P 500. Which has higher valuation and earnings, HCM or TECX? HUTCHMED has higher revenue and earnings than Tectonic Therapeutic. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$838M2.81$100.78MN/AN/ATectonic TherapeuticN/AN/A$12.16M-$5.89-9.19 Do insiders & institutionals have more ownership in HCM or TECX? 8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by company insiders. Comparatively, 9.2% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryTectonic Therapeutic beats HUTCHMED on 9 of the 15 factors compared between the two stocks. Get Tectonic Therapeutic News Delivered to You Automatically Sign up to receive the latest news and ratings for TECX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TECX vs. The Competition Export to ExcelMetricTectonic TherapeuticBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$798.73M$3.09B$5.57B$9.12BDividend YieldN/A1.84%5.31%3.99%P/E Ratio-9.1945.0487.7617.96Price / SalesN/A401.561,224.7575.80Price / CashN/A190.0245.9637.70Price / Book25.424.125.124.71Net Income$12.16M-$40.99M$111.17M$224.24M7 Day Performance15.83%-0.44%2.38%-0.17%1 Month Performance17.26%0.93%3.20%0.60%1 Year PerformanceN/A-1.69%24.70%20.43% Tectonic Therapeutic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TECXTectonic Therapeutic2.3123 of 5 stars$54.14-1.3%$80.50+48.7%N/A$379.44MN/A-9.19120Analyst ForecastNews CoverageHigh Trading VolumeHCMHUTCHMED3.392 of 5 stars$13.64+0.6%$19.00+39.3%+8.2%$2.38B$838M0.001,988Short Interest ↓Positive NewsMIRMMirum Pharmaceuticals3.5686 of 5 stars$48.48+2.0%$57.10+17.8%+84.7%$2.33B$186.37M-24.00140High Trading VolumeCGONCG Oncology2.2357 of 5 stars$30.50-0.9%$63.88+109.4%-19.3%$2.32B$200,000.000.0061Positive NewsJANXJanux Therapeutics3.3753 of 5 stars$43.54-1.3%$89.90+106.5%+407.9%$2.31B$13.05M-37.2130Short Interest ↑PTGXProtagonist Therapeutics3.2367 of 5 stars$38.36+1.8%$53.78+40.2%+51.1%$2.29B$60M14.42120Positive NewsVERAVera Therapeutics2.8791 of 5 stars$34.84+2.7%$68.86+97.6%+2.4%$2.21BN/A-13.3540Analyst ForecastHRMYHarmony Biosciences4.6257 of 5 stars$38.25+0.6%$55.00+43.8%+22.9%$2.18B$582.02M18.13200Insider TradeIBRXImmunityBio2.4075 of 5 stars$3.13-1.3%$13.58+334.0%+2.7%$2.18B$7.33M-3.40590Short Interest ↑Gap DownCNTACentessa Pharmaceuticals3.6034 of 5 stars$16.42-0.2%$25.83+57.3%+106.6%$2.16B$6.85M-10.73200Insider TradeBEAMBeam Therapeutics3.388 of 5 stars$25.91-0.3%$47.67+84.0%+6.2%$2.15B$377.71M-14.72510Analyst UpgradeAnalyst RevisionNews CoverageGap Down Related Companies and Tools Related Companies HUTCHMED Competitors Mirum Pharmaceuticals Competitors CG Oncology Competitors Janux Therapeutics Competitors Protagonist Therapeutics Competitors Vera Therapeutics Competitors Harmony Biosciences Competitors ImmunityBio Competitors Centessa Pharmaceuticals Competitors Beam Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TECX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump loves DeepSeekPresident Trump could be ecstatic. And it's all thanks to DeepSeek. The secretive Chinese startup just r...Weiss Ratings | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
